{"type":"trials","record":{"id":41576,"source_id":"clinicaltrials-gov","external_id":"NCT04504123","title":"MMP-9 Inhibition for Recalcitrant Wet AMD","brief_summary":"Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world. Currently, anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) remain the standard-of-care treatment for wAMD. Previous studies show that about 90% of treated patients lose minimal visual function after 2 years of follow-up. There is still, a subset of 15% patients, incomplete responders, that do not improve and possibly worsen due to the persistence of sub-retinal fluid (with or without intra-retinal fluid) with chronic treatment. The investigators plan to evaluate the effect of oral doxycycline versus placebo on the anatomic and functional outcomes in persistent sub-retinal eye fluid in neovascular wet age-related macular degeneration. This subset are incomplete or non-responders to current anti-VEGF intravitreal therapy.","overall_status":"Recruiting","phases":["PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"University of Iowa","enrollment":50,"countries":["United States"],"start_date":"2020-11-04","completion_date":"2027-03-01","last_update_date":"2026-04-02","source_url":"https://clinicaltrials.gov/study/NCT04504123","editorial_summary":"A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":"50 Years to 99 Years","comparator":"Placebo","organization":"University of Iowa","interventions":["Doxycycline Hyclate","Placebo"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Resolution of the persistent retinal fluid on optical coherence tomography (OCT) — 9 months","Change in optical coherence tomography (OCT) central media thickness (CMT) — 9 months compared to baseline","Change in best corrected visual acuity (BCVA) — 6 months and 9 months compared to Baseline","Number of intravitreal injections (IVI) administered — 6 months and 9 months","Inflammatory mediators matrix metalloproteinases MMP-9 and MMP-9 activity — Baseline, 6 months and 9 months"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","source_has_results":false},"controlled_terms":["Exudative Macular Degeneration","Wet Age-related Macular Degeneration","Doxycycline Hyclate","Placebo"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":100,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04504123","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-11-04 to 2027-03-01","comparator":"Placebo","confidence":"structured-source","population":"ALL · 50 Years to 99 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.836Z","intervention":["Doxycycline Hyclate","Placebo"],"participants":50,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · QUADRUPLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Resolution of the persistent retinal fluid on optical coherence tomography (OCT) — 9 months","Change in optical coherence tomography (OCT) central media thickness (CMT) — 9 months compared to baseline","Change in best corrected visual acuity (BCVA) — 6 months and 9 months compared to Baseline","Number of intravitreal injections (IVI) administered — 6 months and 9 months","Inflammatory mediators matrix metalloproteinases MMP-9 and MMP-9 activity — Baseline, 6 months and 9 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41576","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}